中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 2
Feb.  2017
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2017  >  33(2): 359-363

Mechanism of radiofrequency ablation in treatment of hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2017.02.035

  • Department of Ultrasound,Shengjing Hospital of China Medical University

  • Received Date: 2016-09-18
  • Published Date: 2017-02-20
    Abstract
  • Hepatocellular carcinoma( HCC) is a malignant tumor with high incidence and mortality rates around the world.Radiofrequency ablation( RFA) is an effective therapy for HCC,especially in patients who experience recurrence after surgery for liver cancer,who are complicated by liver dysfunction and unable to undergo surgical resection,and who have multiple liver tumors and undergo palliative treatment.RFA can significantly improve patients' survival time and quality of life.This article reviews the mechanism of RFA in the treatment of HCC from the aspects of direct and indirect injuries and helps to further understand the role of RFA in local and systemic treatment of HCC,which has a potential value for multidisciplinary treatment of HCC in future.

     

    • FullText(HTML)
    • References(46)
  • [1]McG LYNN KA,PETRICK JL,LONDON WT.Global epidemiology of hepatocellular carcinoma:an emphasis on demographic and regional variability[J].Clin Liver Dis,2015,19(2):223-238.
    [2]EL-SERAG HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J].Gastroenterology,2012,142(6):1264-1273.
    [3]WONG R,FRENETTE C.Updates in the management of hepatocellular carcinoma[J].Gastroenterol Hepatol(NY),2011,7(1):16-24.
    [4]FORNER A,LLOVET JM,BRUIX J.Hepatocellular carcinoma[J].Lancet,2012,379(9822):1245-1255.
    [5]AKOAD ME,POMFRET EA.Surgical resection and liver transplantation for hepatocellular carcinoma[J].Clin Liver Dis,2015,19(2):381-399.
    [6]Ministry of Health of the People's Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
    [7]ROSSI S.Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma[J].JIntervent Radiol,1993,8:97-103.
    [8]LENCIONI R.Loco-regional treatment of hepatocellular carcinoma[J].Hepatology,2010,52(2):762-773.
    [9]LIVRAGHI T,GOLDBERG SN,LAZZARONI S,et al.Small hepatocellular carcinoma:treatment with radio-frequency ablation versus ethanol injection[J].Radiology,1999,210(3):655-661.
    [10]NIKFARJAM M,MALCONTENTI-WILSON C,CHRISTOPHI C.Focal hyperthermia produces progressive tumor necrosis independent of the initial thermal effects[J].J Gastrointest Surg,2005,9(3):410-417.
    [11]MERTYNA P,HINES-PERALTA A,LIU Z,et al.Radiofrequency ablation:variability in heat sensitivity in tumors and tissues[J].J Vasc Interv Radiol,2007,18(5):647-654.
    [12]CHU KF,DUPUY DE.Thermal ablation of tumours:biological mechanisms and advances in therapy[J].Nat Rev Cancer,2014,14(3):199-208.
    [13]AHMED M,BRACE CL,LEE Jr FT,et al.Principles of and advances in percutaneous ablation[J].Radiology,2011,258(2):351-369.
    [14]ZHOU Y,HAN G,WANG Y,et al.Radiofrequency heat-enhanced chemotherapy for breast cancer:towards interventional molecular image-guided chemotherapy[J].Theranostics,2014,4(11):1145.
    [15]ZHANG F,LE T,WU X,et al.Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line:monitoring with dualmodality imaging---preclinical study[J].Radiology,2014,270(2):400-408.
    [16]DICKSON JA,CALDERWOOD SK.Temperature range and selective sensitivity of tumors to hyperthermia:a critical review[J].Ann N Y Acad Sci,1980,335(1):180-205.
    [17]OVERGAARD K,OVERGAARD J.Investigations on the possibility of a thermic tumour therapy.I.Short-wave treatment of a transplanted isologous mouse mammary carcinoma[J].Eur J Cancer,1972,8(1):65-78.
    [18]THOMSEN S.Pathologic analysis of photothermal and photomechanical effects of laser-tissue interactions[J].Photochem Photobiol,1991,53(6):825-835.
    [19]OVERGAARD J,SUIT HD.Time-temperature relationship in hyperthermic treatment of malignant and normal tissue in vivo[J].Cancer Res,1979,39(8):3248-3253.
    [20]MATTHEWSON K,COLERIDGE-SMITH P,O'SULLIVAN JP,et al.Biological effects of intrahepatic neodymium:yttrium-aluminum-garnet laser photocoagulation in rats[J].Gastroenterology,1987,93(3):550-557.
    [21]van HILLEGERSBERG R,de WITTE MT,KORT WJ,et al.Water-jet-cooled Nd:YAG laser coagulation of experimental liver metastases:correlation between ultrasonography and histology[J].Lasers Surg Med,1993,13(3):332-343.
    [22]YANG W,CUI M,LEE J,et al.Heat shock protein inhibitor,quercetin,as a novel adjuvant agent to improve radiofrequency ablation-induced tumor destruction and its molecular mechanism[J].Chin J Cancer Res,2016,28(1):19.
    [23]FENG H,ZENG Y,WHITESELL L,et al.Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity[J].Blood,2001,97(11):3505-3512.
    [24]MELCHER A,TODRYK S,HARDWICK N,et al.Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression[J].Nat Med,1998,4(5):581-587.
    [25]LANNEAU D,BRUNET M,FRISAN E,et al.Heat shock proteins:essential proteins for apoptosis regulation[J].J Cell Mol Med,2008,12(3):743-761.
    [26]CHALMIN F,LADOIRE S,MIGNOT G,et al.Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloidderived suppressor cells[J].J Clin Invest,2010,120(2):457-471.
    [27]SPISEK R,CHARALAMBOUS A,MAZUMDER A,et al.Bortezomib enhances dendritic cell(DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells:therapeutic implications[J].Blood,2007,109(11):4839-4845.
    [28]SCHUELLER G,KETTENBACH J,SEDIVY R,et al.Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation in an animal model[J].Oncol Rep,2004,12(3):495-499.
    [29]SCHUELLER G,KETTENBACH J,SEDIVY R,et al.Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo[J].Int J Oncol,2004,24(3):609-613.
    [30]HAEN SP,GOUTTEFANGEAS C,SCHMIDT D,et al.Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation[J].Cell Stress Chaperones,2011,16(5):495-504.
    [31]TSAN MF,GAO B.Heat shock proteins and immune system[J].JLeukoc Biol,2009,85(6):905-910.
    [32]DUAN X,LI TF,ZHOU GF,et al.Transcatheter arterial embolization combined with radiofrequency ablation activates CD8+T-cell infiltration surrounding residual tumors in the rabbit VX2 liver tumors[J].Onco Targets Ther,2016,9:2835-2844.
    [33]THIMME R,NEAGU M,BOETTLER T,et al.Comprehensive analysis of the alpha-fetoprotein-specific CD8+T cell responses in patients with hepatocellular carcinoma[J].Hepatology,2008,48(6):1821-1833.
    [34]MIZUKOSHI E,YAMASHITA T,ARAI K,et al.Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma[J].Hepatology,2013,57(4):1448-1457.
    [35]BEHM B,DI FAZIO P,MICHL P,et al.Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation[J].Gut,2016,65(1):134-143.
    [36]ZERBINI A,PILLI M,PENNA A,et al.Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses[J].Cancer Res,2006,66(2):1139-1146.
    [37]ZERBINI A,PILLI M,FAGNONI F,et al.Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation[J].J Immunother,2008,31(3):271-282.
    [38]NOBUOKA D,MOTOMURA Y,SHIRAKAWA H,et al.Radiofrequency ablation for hepatocellular carcinoma induces glypican-3peptide-specific cytotoxic T lymphocytes[J].Int J Oncol,2012,40(1):63-70.
    [39]de BETHLENFALVA-HORA CE,MERTENS JC,PIGUET AC,et al.Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma[J].Clin Sci(Lond),2014,126(3):243-252.
    [40]SHI L,CHEN L,WU C,et al.PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor[J].Clin Cancer Res,2016,22(5):1173-1184.
    [41]IKEMOTO T,SHIMADA M,YAMADA S.Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation[J].Hepatol Res,2017,47(1):23-30.
    [42]ERINJERI JP,THOMAS CT,SAMOILIA A,et al.Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10[J].J Vasc Interv Radiol,2013,24(8):1105-1112.
    [43]ROZENBLUM N,ZEIRA E,BULVIK B,et al.Radiofrequency ablation:inflammatory changes in the periablative zone can induce global organ effects,including liver regeneration[J].Radiology,2015,276(2):416-425.
    [44]AHMED M,KUMAR G,MOUSSA M,et al.Hepatic radiofrequency ablation-induced stimulation of distant tumor growth is suppressed by c-Met inhibition[J].Radiology,2015,279(1):103-117.
    [45]AHMED M,KUMAR G,NAVARRO G,et al.Systemic siRNAnanoparticle-based drugs combined with radiofrequency ablation for cancer therapy[J].PLoS One,2015,10(7):e0128910.
    [46]YIN Y,NI CF,LI Z,et al.Therapeutic comparison between radiofrequency ablation and percutaneous ethanol injection in treatment of primary liver cancer:a meta-analysis[J].J Clin Hepatol,2015,31(6):918-921.(in Chinese)印于,倪才方,李智,等.射频消融与经皮无水乙醇注射治疗原发性肝癌疗效对比的Meta分析[J].临床肝胆病杂志,2015,31(6):918-921.
    • Relative Articles

  • Relative Articles

    [1]Yuan WEN, Juanjuan ZHU. Clinical efficacy of double plasma molecular absorption system and sequential plasma exchange combined with continuous renal replacement therapy in treatment of acute-on-chronic liver failure with acute kidney injury[J]. Journal of Clinical Hepatology, 2024, 40(3): 556-561. doi: 10.12449/JCH240319
    [2]Nianchen LIU, Jie BAI, Chen LIANG, Li BAI, Shuang LIU, Zhongping DUAN, Sujun ZHENG. UGT1A1 gene polymorphisms in patients with Gilbert syndrome and Crigler-Najjar syndrome type Ⅱ[J]. Journal of Clinical Hepatology, 2022, 38(2): 397-401. doi: 10.3969/j.issn.1001-5256.2022.02.026
    [3]ZENG Jing, GE WenSong, YANG RuiXu, FAN JianGao, WANG BaoCan. Crigler-Najjar syndrome type Ⅱ:A case report and literature review[J]. Journal of Clinical Hepatology, 2020, 36(11): 2539-2541. doi: 10.3969/j.issn.1001-5256.2020.11.030
    [4]Jia Lei, Wen XinWei, Li HaiYang. Effect of hepatocyte transplantation in treatment of rats with liver cirrhosis and small-for-size syndrome[J]. Journal of Clinical Hepatology, 2020, 36(5): 1038-1042. doi: 10.3969/j.issn.1001-5256.2020.05.018
    [5]Wu YiChen, Yao HongYu, Wang KaiLi, Jiang QiYu, Liu Chang, Xing HanQian, Liu SuXia, You ShaoLi, Zhao Jun. Effect of plasma exchange on bioactivity of peripheral blood CD34+ cells in patients with acute-on-chronic (subacute) liver failure[J]. Journal of Clinical Hepatology, 2018, 34(11): 2383-2387. doi: 10.3969/j.issn.1001-5256.2018.11.023
    [6]Zhou Jian, Wan Hong, Yang ZhengMao, Wang ZhaoXun. Clinical effect of plasma perfusion combined with plasma exchange in treatment of patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2017, 33(4): 715-718. doi: 10.3969/j.issn.1001-5256.2017.04.023
    [7]Hou HuanRong, Shang Jia, Kang Yi, Li YuKui, Ceng YanLi, Ding GangQiang, Mao ZhongShan, Xiao ErHui. Clinical effect of plasma exchange combined with hemofiltration in patients with subacute liver failure induced by antitubercular agents[J]. Journal of Clinical Hepatology, 2016, 32(2): 342-346. doi: 10.3969/j.issn.1001-5256.2016.02.030
    [8]Wu YuNan, Peng JianPing, Huang YuHong, Yang Hang, Sun KeWei. Type II Crigler-Najjar syndrome: a report of one case[J]. Journal of Clinical Hepatology, 2016, 32(4): 776-778. doi: 10.3969/j.issn.1001-5256.2016.04.038
    [9]Zhang LiangJie, Chen HuiJuan, Zhao ShouSong. Effects of artificial liver plasma exchange on cytokines in patients with liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 578-581. doi: 10.3969/j.issn.1001-5256.2015.04.024
    [10]Tan YanFang, Li ShuangJie, Jiang Tao, Ou YangWenXian. Case report of Crigler-Najjar syndrome type I[J]. Journal of Clinical Hepatology, 2015, 31(8): 1328-1329. doi: 10.3969/j.issn.1001-5256.2015.08.037
    [11]Zhang Lin, Zhao ShouSong. Clinical efficacy of plasma exchange therapy in treatment of liver failure[J]. Journal of Clinical Hepatology, 2014, 30(10): 1015-1019. doi: 10.3969/j.issn.1001-5256.2014.10.010
    [12]Hu QiJiang, Jiang YingAn. Evaluation of the therapeutic efficacy of lamivudine combined with plasma exchange for treating acute-on-chronic hepatitis B liver failure [J]. Journal of Clinical Hepatology, 2013, 29(2): 107-109.
    [13]Zhou Jian, Wan Hong. Relationship between changes in serum cytokine levels after artificial liver therapy and clinical prognosis in patients with liver failure[J]. Journal of Clinical Hepatology, 2013, 29(7): 535-537. doi: 1001-5256 (2013) 07-0535-03
    [14]Zhang WenHua, Jia WenLing, Zhou ZiYing, Tang HaiTao, Wang FengMei. Investigation on the method and safety of the non-heparinized plasma exchange therapy in treating patients with hepatic failure[J]. Journal of Clinical Hepatology, 2012, 28(1): 50-52.
    [15]Liao JinMao, Li ZhuoRi, Hu XiaoXuan. The therapeutic effect of plasma exchange therapy in patients with severe hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(4): 302-304.
    [16]Lu WeiYing, Du XiuPing, Sun LianNa, Zhang YinHua, Xue JianHua. Analysis of the therapeutic effect of plasma exchange combined with Lamivudine in severe chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2010, 26(6): 589-590.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(7)

    1. 陈茜蕾，慕永平，刘平. 肝硬化门静脉高压症中医证候病机特点及治疗进展. 中华中医药杂志. 2023(06): 2734-2738 .
    2. 高丽芳. 活血化瘀通络法治疗肝硬化合并上消化道出血肝脾血瘀证的临床观察. 山西中医药大学学报. 2023(06): 636-640 .
    3. 冯颖，时克，张晓华，杨莉，王宪波. 抗肝纤维化中药治疗对肝硬化并发肠系膜上静脉栓塞患者预后的影响. 临床肝胆病杂志. 2022(07): 1534-1539 . 本站查看
    4. 徐珍，梁斌. 裸花紫珠颗粒辅助治疗慢性乙肝肝硬化所致食管胃静脉曲张出血的临床观察. 江西医药. 2022(08): 940-942 .
    5. 齐小泉. 奥曲肽联合去氨加压素治疗肝硬化合并食管胃底静脉曲张破裂出血的临床效果. 临床合理用药杂志. 2021(35): 95-97 .
    6. 郑延和. 复方甘草酸苷联合奥曲肽对肝硬化上消化道出血的疗效. 甘肃医药. 2021(12): 1093-1095 .
    7. 王波，曹雪，唐航，李子瑜，刘楷煜，牛犇. 针刀疗法联合中药熏蒸治疗旋前圆肌综合征. 吉林中医药. 2020(01): 124-127 .

    Other cited types(2)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 8.8 %FULLTEXT: 8.8 %META: 88.0 %META: 88.0 %PDF: 3.1 %PDF: 3.1 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.2 %其他: 5.2 %其他: 0.2 %其他: 0.2 %Auckland: 0.2 %Auckland: 0.2 %India: 0.4 %India: 0.4 %Portugal: 0.2 %Portugal: 0.2 %[]: 0.2 %[]: 0.2 %上海: 3.5 %上海: 3.5 %东莞: 0.4 %东莞: 0.4 %北京: 13.6 %北京: 13.6 %南京: 0.2 %南京: 0.2 %南充: 0.2 %南充: 0.2 %南宁: 0.4 %南宁: 0.4 %台州: 0.2 %台州: 0.2 %吉林: 0.7 %吉林: 0.7 %天津: 0.2 %天津: 0.2 %广州: 0.4 %广州: 0.4 %张家口: 1.5 %张家口: 1.5 %惠州: 0.4 %惠州: 0.4 %成都: 0.4 %成都: 0.4 %昆明: 0.2 %昆明: 0.2 %杭州: 0.9 %杭州: 0.9 %沈阳: 0.2 %沈阳: 0.2 %济南: 0.2 %济南: 0.2 %湖州: 0.2 %湖州: 0.2 %湛江: 0.6 %湛江: 0.6 %漯河: 0.2 %漯河: 0.2 %芒廷维尤: 31.3 %芒廷维尤: 31.3 %苏州: 0.4 %苏州: 0.4 %莫斯科: 1.1 %莫斯科: 1.1 %衢州: 0.6 %衢州: 0.6 %西宁: 33.1 %西宁: 33.1 %辽阳: 0.2 %辽阳: 0.2 %长春: 0.6 %长春: 0.6 %长沙: 1.5 %长沙: 1.5 %长治: 0.4 %长治: 0.4 %青岛: 0.2 %青岛: 0.2 %香港: 0.2 %香港: 0.2 %其他其他AucklandIndiaPortugal[]上海东莞北京南京南充南宁台州吉林天津广州张家口惠州成都昆明杭州沈阳济南湖州湛江漯河芒廷维尤苏州莫斯科衢州西宁辽阳长春长沙长治青岛香港

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2395) PDF downloads(608) Cited by(9)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1659]YesterdayPV[2864]TodayIP[145]TodayPV[236]Online[6]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return